Immutep Ltd has released a press release.
Immutep receives positive scientific advice from EMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial
- US patent granted for Efti with PD-1 pathway inhibitor
- Immutep granted US patent for IMP761 agonist LAG-3 antibody
- A$80 million fully underwritten equity raising
- Charles River Laboratories to run IMP761 Toxicology Study
Later from Immutep
- Appendix 4E & 2023 Full Year Statutory Accounts
- Commercial Scale Manufacturing of Efti for Clinical Trials
- Immutep announces publication of ESMO 2023 abstracts
- Excellent Overall Survival in Non-Small Cell Lung Cancer
- Webcast slides for new Efti clinical data in 1st line NSCLC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep